{"entity":{"id":"biond-biologics","kind":"company","name":"Biond Biologics","aka":["Biond Biologics Ltd."],"tldr":"Biond Biologics is an Israeli company making antibodies that release new immune brakes so the immune system can attack tumours. Its lead antibody, BND-22, is in a phase 2 study with standard immunotherapy, and BND-35 has finished an early safety study.","summary":"Biond Biologics Ltd., at Misgav Industrial Park, Israel, is a private, clinical-stage company developing first-in-class immunotherapies for cancer and immune-mediated diseases. BND-22 is an anti-ILT2 (LILRB1) checkpoint antibody, earlier partnered with Sanofi as SAR444881; Biond announced in March 2025 that it would regain full rights and in August 2025 started a phase 2 study with anti-PD-1 therapy. BND-67 is a first-in-class antibody that targets CD28 shedding and is in a phase 1 study. BND-35 is an anti-ILT3 (LILRB4) antibody aimed at suppressive myeloid cells; first patient dosing in its phase 1 study (NCT06274437) was announced in June 2024, and in October 2024 Biond agreed a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, to test BND-35 with cetuximab. The company website says the BND-35 monotherapy study is completed, while the ClinicalTrials.gov record lists it as terminated. In June 2026 it announced the closing of an USD 8 million investment and collaboration with the Guangzhou-Israel Biotechnology Fund. Its first registered cancer trial as lead sponsor, NCT06274437, was posted on ClinicalTrials.gov in February 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.biondbio.com/"},{"label":"ClinicalTrials.gov: phase 1 trial of BND-35 (NCT06274437)","url":"https://clinicaltrials.gov/study/NCT06274437"},{"label":"Company press releases","url":"https://www.biondbio.com/press/"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["monoclonal-antibody","checkpoint-inhibitor"],"targets":["lilrb1","cd28"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on 29 October 2026: biondbio.com home, about, BND-35, press and contact pages. The GIBF release itself (a PDF) was seen by title only.","Founding year not stated on the company website. Earlier BND-22 trials were run by Sanofi and are not counted as Biond-sponsored. No LILRB4 target record exists in OnCo.","Trial facts from the ClinicalTrials.gov record NCT06274437, read on 29 October 2026."],"hq":"Misgav","country":"IL","companyType":"biotech","website":"https://www.biondbio.com/","stage":"startup","investors":[],"funding":[{"round":"Strategic investment","year":2026,"amountUsd":8000000,"source":"https://www.biondbio.com/wp-content/uploads/2026/06/Biond-Biologics_GIBF-8M-round.pdf","note":"Investment and collaboration with the Guangzhou-Israel Biotechnology Fund (GIBF); amount from the release title on the company press page."}]},"route":"/companies/biond-biologics/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"target":[{"id":"cd28","kind":"target","name":"CD28","route":"/targets/cd28/"},{"id":"lilrb1","kind":"target","name":"LILRB1 (ILT2)","route":"/targets/lilrb1/"}]}}